Iridium Holders Approve Rocket Lab's $54 Deal

Iridium holders get $27 in cash plus Rocket Lab stock per share, a collared exchange valued at a notional $54. Closing is expected by mid-2027, per the same release, pending regulatory approval.

What the Vote Actually Decided

A shareholder vote is not a closing. On September 24, 2026, Iridium held a special meeting where its stockholders adopted the merger agreement with Rocket Lab. What it is not: a closed deal.

What Will Iridium Shareholders Actually Receive?

Each Iridium share converts into a mix of cash and Rocket Lab stock, not a flat check. Per GovConWire's reporting, "Iridium stockholders will receive $27 per share in cash plus Rocket Lab common stock at an exchange ratio subject to a collar, bringing the notional value to $54 per share." The word doing the work there is "collar." The number of Rocket Lab shares you get is set within a band. The actual value at closing moves with Rocket Lab's stock price, not with the headline $54 figure.

Deal term	What's known
Cash per share	$27.00
Stock component	Rocket Lab common stock, exchange ratio subject to a collar
Notional value	$54.00 per Iridium share
Cash financing	$1.94B at-the-market equity offering, completed

If you want the mechanics of how a merger agreement's terms actually get disclosed, and where to check them yourself rather than take a headline's word for it, I walked through the filing itself in What Is a Merger Sub? Inside the $4.5B Crinetics/Vertex Deal. Same habit applies here: pull the definitive proxy statement, not a summary of it.

Why Rocket Lab Wants Iridium

This isn't two companies in the same business consolidating. That's the first thing I look for, a habit left over from vetting acquisition targets and startups for a Fortune 500 innovation team: does the buyer already own the thing being described, or just say it does. Iridium runs a constellation business built on connectivity, not launch. Rocket Lab builds the hardware and gets things into orbit.

Iridium's own CEO framed it the same way. Per GovConWire, Matt Desch said: "Today's vote is an important milestone toward bringing together two companies with complementary capabilities, a shared commitment to innovation, and deep experience supporting some of the world's most critical missions." That's standard deal-announcement language, not proof the combination will perform. Take the stated rationale for what it is: the reason the two boards agreed to the deal, not a guarantee it delivers.

How Rocket Lab Is Paying For the Cash Piece

$27 a share in cash on a company Iridium's size is real money, and I want to see how an acquirer plans to fund that before I trust a headline number. Rocket Lab didn't wait for closing. Per GovConWire, "the company completed a $1.94 billion at-the-market equity offering this month, issuing 29.3 million shares to cover the cash portion of the purchase." That's dilution for existing Rocket Lab shareholders, done now, ahead of a close that's still a year or more out.

The same report says Rocket Lab "separately terminated a $3.6 billion bridge facility that had been lined up when the merger agreement was signed, and Iridium amended its term loan to carve the acquisition out of the change-of-control provisions." In plain terms: the emergency-loan backstop is gone, the equity raise did the job instead, and Iridium's existing lenders agreed not to treat the merger as a default trigger.

Why This Matters If You Read Private Deal Term Sheets, Not Just Tickers

I'm not writing this because AIN calls stock moves. We don't, and we won't start with IRDM and RKLB. I'm writing it because the mechanics in this filing are the same mechanics you'll find in a private deal's term sheet, and most investors gloss over them there too. A collar on a public exchange ratio works the same way a valuation mechanism does when a sponsor restructures a private deal mid-hold: it moves your actual payout inside a range you never negotiated. I covered that instinct in PE Secondary Stakes: Why KKR's Flow Control Deal Matters: read the mechanism, not the headline number. A right of first refusal buried in a term sheet works the same trick, it looks like boilerplate until it locks you out of an exit, which I broke down in Right of First Refusal: The Clause That Can Lock You In or Kill Your Deal. Downside first, every time: know how the number can shrink before you get excited about how big it looks today.

Common Mistakes Reading This Kind of Merger Vote

• Treating "approved" as "closed." A shareholder vote clears one condition. Regulatory approval is the one still outstanding, and it's the one that can still change or kill terms.
• The ~81%-of-outstanding-shares figure is the more meaningful ownership number, and it still leaves roughly a fifth of shares that didn't vote in favor or didn't vote at all.
• Treating the $54 notional value as a fixed payout. The stock portion is set by an exchange ratio inside a collar. Your actual per-share value at closing depends on where Rocket Lab's stock trades then, not on the headline number reported today.
• Skipping the financing detail. A cash-and-stock deal is only as solid as the acquirer's ability to fund the cash piece. Rocket Lab already raised the $1.94 billion via equity rather than debt. That's a different risk profile than a deal still relying on an unfunded bridge loan.

FAQ

Is Rocket Lab buying Iridium? Yes. The deal hasn't closed. Regulatory approvals remain, and completion is targeted for mid-2027.

Who will buy Iridium? Rocket Lab Corporation, the Long Beach, California launch and space-systems company. Iridium becomes Rocket Lab's indirect wholly owned subsidiary ahead of a subsequent merger, per an 8-K filing summary.

What's the latest Rocket Lab stock news tied to this deal? RKLB traded up 0.7% after hours on the vote day and is up nearly 6% year to date, per Yahoo Finance. IRDM, up 187% year to date on the same report, slipped 0.29% the same day.

Is Iridium a strong buy? AIN doesn't make buy or sell calls on individual securities. What's documented: shareholders approved a deal valuing Iridium at a notional $54 a share, and the outcome from here turns on regulatory approval, not further shareholder action.

The Bottom Line

Don't assume the $54 figure is what you'll actually receive. The notional number is a headline; the collar math is the payout.

Want AIN's next read on a deal like this? That's what the free AIN briefing is for — sign up and get the next one in your inbox.

Educational content only. Not investment, tax, or legal advice. Not an offer or solicitation to buy or sell securities. Past performance does not guarantee future results. Private-market investments are illiquid and involve risk of loss, including total loss of capital. Consult qualified advisers. Angel Investors Network is not a broker-dealer or investment adviser.